OMER vs MTA Comparison

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA, with the majority generated from Brazil.